Research Foundation For Mental Hygiene Inc

NYS OASAS SOR 4 - THE NEW YORK STATE (NYS) OFFICE OF ADDICTION SERVICES AND SUPPORTS (OASAS) WILL CONTINUE TO FUND THE REGIONAL NETWORK APPROACH TO PREVENTION, HARM REDUCTION, TREATMENT, AND RECOVERY TO SERVE NYS RESIDENTS WHO HAVE AN OPIOID USE DISORDER (OUD) OR STIMULANT USE DISORDER (STUD), ARE AT RISK FOR DEVELOPING AND OUD OR STUD, OR ARE IN RECOVERY FROM AN OUD OR STUD. THE REGIONAL NETWORK APPROACH, INITIATED UNDER THE 2020 STATE OPIOID RESPONSE GRANT, GAVE PROVIDERS THE OPPORTUNITY TO DEVELOP A REGIONAL NETWORK OF CARE FOR OUD AND STUD THROUGH SHARED KNOWLEDGE, THE IDENTIFICATION OF OPPORTUNITIES FOR PARTNERSHIP AND THE SHARING OF, OR CO CREATION OF, PROGRAMS. NETWORKS WILL CONTINUE TO INVEST IN REGIONAL INITIATIVES AIMED AT IMPROVING DATA QUALITY, PROMOTING STAFF TRAINING/WELLNESS AND DEVELOPING SHARED REFERRAL SYSTEMS USING TECHNOLOGY. NETWORK PROVIDERS FORMALIZED COLLABORATIONS WITH MEMORANDUMS OF UNDERSTANDING, BUILT NEW SERVICES, AND JOINTLY PURSUED PROGRAM FUNDING OPPORTUNITIES. WITHIN EACH OF THE 13 REGIONAL NETWORKS, PROVIDERS WILL CONTINUE DELIVERING SERVICES INCLUDING: EXPANDING ACCESS TO MEDICATION FOR OPIOID USE DISORDER (MOUD); LINKING HOSPITAL EMERGENCY DEPARTMENTS AND URGENT MEDICAL CARE CENTERS TO PEER SUPPORTS, OUTPATIENT TREATMENT PROGRAMS, AND ADDICTION MEDICINE SPECIALISTS TO IMPROVE INTERVENTION AND INITIATION OF MOUD; LINKING FEDERALLY QUALIFIED HEALTH CENTERS TO OUTPATIENT TREATMENT PROGRAMS TO INCREASE PATIENT ACCESS TO MOUD AND LEVERAGE RESOURCES AND EXPERTISE ACROSS PATIENT SETTINGS; INTEGRATING AND SUPPORTING THE PEER WORKFORCE WITHIN TREATMENT AND RECOVERY SETTINGS; DELIVERING RECOVERY SERVICES, INCLUDING PEER SERVICES, HOUSING ASSISTANCE, VOCATIONAL SUPPORT, NON-MEDICAL TRANSPORTATION, AND SERVICES FOR THE CHILDREN AND FAMILIES OF THOSE IN RECOVERY; INNOVATIVE TELEHEALTH STRATEGIES IN RURAL AND UNDERSERVED AREAS TO INCREASE THE CAPACITY OF COMMUNITIES TO SUPPORT OUD/STUD TREATMENT AND RECOVERY; OPERATING ACCESS AND SUPPORT HOTLINES TO SUPPORT REGIONAL NETWORKS; PROVIDING SERVICES AND SUPPORTS SPECIFICALLY DESIGNED TO MEET THE NEEDS OF THE YOUTH AND YOUNG ADULT POPULATIONS; PARTNERING WITH EXISTING RECOVERY COMMUNITY AND OUTREACH CENTERS AND YOUTH CLUBHOUSES; PROVIDING SERVICES AND SUPPORTS THAT TARGET CRIMINAL LEGAL SYSTEM POPULATIONS; AND MAINTAINING A JUSTICE-INVOLVED PEER PROGRAM TO ADDRESS SIGNIFICANT CHALLENGES UPON REENTRY INTO THE COMMUNITY FROM THE CRIMINAL LEGAL SYSTEM. ADDITIONALLY, OASAS WILL CONTINUE TO SUPPORT THE DISTRIBUTION OF HARM REDUCTION SUPPLIES THROUGH OPIOID OVERDOSE PREVENTION COMMUNITY TRAININGS, AN OASAS WEB-BASED HARM REDUCTION SUPPLY ORDERING PORTAL, AND HARM REDUCTION VENDING MACHINES ACROSS THE STATE. PROJECT GOALS ARE TO: ENHANCE COORDINATION AND DELIVERY OF COMPREHENSIVE PREVENTION SERVICES THROUGH REGIONAL NETWORKS; INCREASE THE NUMBER OF PERSONS WITH OUD OR STUD RECEIVING TREATMENT THROUGH PEER OUTREACH AND ENGAGEMENT ENCOUNTERS; INCREASE THE CAPACITY OF THE SUD PROVIDERS TO PROVIDE HARM REDUCTION SERVICES TO PEOPLE WHO USE DRUGS; INCREASE THE NUMBER OF PERSONS WITH OUD OR STUD RECEIVING INITIAL OR RE-ENGAGEMENT IN RECOVERY-RELATED SERVICES BY ESTABLISHING AND STRENGTHENING LINKAGES BETWEEN PROGRAMS; AND INCREASE THE NUMBER OF VULNERABLE PERSONS WITH OUD OR STUD RECEIVING RECOVERY-RELATED SERVICES THROUGH EXPANSION AND ENHANCEMENT OF SERVICES AND ACCESS. THIS PROJECT ANTICIPATES SERVING APPROXIMATELY 5,100 PERSONS PER YEAR THROUGH PREVENTION SERVICES, 22,000 PER YEAR THROUGH TREATMENT SERVICES, AND 16,200 PER YEAR THROUGH RECOVERY SERVICES.

NYS OASAS SOR 3 - NEW YORK PROPOSES TO CONTINUE INVESTING IN REGIONAL NETWORKS TO BUILD CROSS-SYSTEM COLLABORATION AND INCREASE CONNECTIONS TO CARE. NEW YORK FUNDED REGIONAL NETWORKS THROUGH SOR 2 TO PROVIDE SERVICES ACROSS THE CONTINUUM OF CARE TO CREATE A WHOLISTIC APPROACH TO COMMUNITY INTERVENTION AT THE REGIONAL LEVEL. THIS INCLUDED UTILIZING MEASURES TO ENCOURAGE NETWORK AND PROVIDER COLLABORATION TO ATTAIN FURTHER INCREASES IN MAT INITIATION, MAT ADHERENCE, CONTINUATION OF ENGAGEMENT IN TREATMENT, AND CONTINUITY BETWEEN LEVELS OF CARE, AS WELL AS DEMONSTRABLY IMPROVED OUTREACH TO PEOPLE WHO USE OPIOIDS AND/OR STIMULANTS WHO ARE NOT ENGAGED IN CARE. THE NETWORKS INCORPORATED THE FULL CONTINUUM OF OASAS SERVICES INCLUDING PREVENTION AND RECOVERY INTO THE NETWORK AND INCLUDED A REPRESENTATIVE FROM EACH ON THE LEADERSHIP TEAM. EACH NETWORK WAS ENCOURAGED TO INCLUDE A FULL ARRAY OF SUD SERVICES INCLUDING HARM REDUCTION, CRISIS SERVICES, AND EVIDENCE-BASED PREVENTION PRACTICES. EACH OF THE NETWORKS HAS HAD SUCCESS IN BRINGING PROVIDERS TOGETHER, IMPLEMENTING SCOPES OF WORK AS PROPOSED IN THEIR APPLICATION, AND SOLVING PROBLEMS RELATED TO GAPS AND BARRIERS TO CARE IN THEIR COMMUNITIES. AN EXAMPLE OF THIS IS THE RECENT OPPORTUNITY THROUGH ANOTHER FUNDING SOURCE TO IMPLEMENT TRANSPORTATION WITHIN THE REGION FOR NON-MEDICAL SERVICES TO SUPPORT RECOVERY. EACH OF THE NETWORKS APPLIED FOR THE FUNDING WITH UNIQUE SOLUTIONS BASED ON THE NEEDS OF THEIR REGION CAPITALIZING ON THE COLLABORATION OF THE NETWORK AND THE CURRENT SUD ASSETS IN THE REGION. THROUGH A REQUEST FOR APPLICATIONS, EACH REGIONAL NETWORK WILL IDENTIFY THE INNOVATIVE MODELS OF SERVICE PROVISION IN PREVENTION, TREATMENT, AND RECOVERY THAT ADDRESS THE EXISTING NEEDS OF THEIR POPULATION. OASAS WILL PROVIDE A LIST OF SERVICES WHICH THE REGIONAL NETWORK WILL SELECT FROM TO BEST ADDRESS LOCAL NEEDS. AMONG THESE SERVICES, OASAS WILL PLACE AN EMPHASIS ON IN-COMMUNITY SERVICES AS MODELED IN THE CENTER OF TREATMENT INNOVATION (COTI) PROGRAM INITIATED UNDER STR AND CONTINUED THROUGH THE SOR GRANT. THE MODEL INCLUDES TRANSPORTATION AND MOBILE TREATMENT, THE USE OF A PEER OUTREACH WORKFORCE, TELE-PRACTICE AND LINKAGES MENTAL HEALTH AND MEDICAL SERVICES. OTHER MODELS AND TYPES OF SERVICE THE NETWORKS WILL INCLUDE ARE: LINKING EMERGENCY ROOMS TO PEERS, OUTPATIENT TREATMENT PROGRAMS, AND ADDICTION MEDICINE SPECIALISTS TO IMPROVE INTERVENTION AND INITIATION OF MEDICATION FOR OPIOID USE DISORDER; LINKING OUTPATIENT TREATMENT PROVIDERS TO FEDERALLY QUALIFIED HEALTH CENTERS; IMPROVE PROVIDER CAPACITY TO USE QUALITY IMPROVEMENT STRATEGIES TO INCREASE ACCESS TO MAT INITIATION, MAT ADHERENCE AND IMPROVED RATES OF FOLLOW UP AFTER HIGH INTENSITY SERVICES; IMPROVE SUD PROVIDER NETWORK COLLABORATION FOR SHARED AND AGGREGATED DATA ACROSS A NETWORK OF PROVIDERS, IMPLEMENTATION OF COORDINATED PREVENTION, CLINICAL AND PEER INTERVENTIONS ACROSS THE NETWORK; AND INCREASE POSITIVE FAMILY MANAGEMENT; ADULT ORIENTED RECOVERY CENTERS AND YOUTH CLUBHOUSES TO PROMOTE SUBSTANCE FREE POSITIVE SOCIAL ACTIVITIES TO PROMOTE RECOVERY. THE EXISTING REGIONAL NETWORKS PROVIDE AN OPPORTUNITY FOR THE STATE TO MEET THE GOALS OF THE SOR GRANT AT A REGIONAL LEVEL, ACROSS THE STATE TO ENSURE UNIVERSAL ACCESS TO OUD IDENTIFICATION, OUTREACH, HARM REDUCTION SERVICES, MEDICATION ACCESS, PREVENTION, AND RECOVERY SUPPORT.

NYS OASAS SOR 2020

THE NEW YORK STATE OFFICE OF MENTAL HEALTH

NYS OASAS SOR

CRISIS COUNSELING

HIV CENTER FOR CLINICAL AND BEHAVIOR STUDIES

PROMOTING THE READINESS OF MINORS IN SUPPLEMENTAL SECURITY INCOME (PROMISE)

CLINICAL TRIALS NETWORK: LONG ISLAND REGIONAL NODE

CELL AND MOLECULAR PATHOBIOLOGY OF ALZHEIMER'S DISEASE

THE NEW YORK STATE OFFICE OF ALCOHOLISM AND SUBSTANCE ABUSE SERVICES (OASAS) IN PARTNERSHIP WITH THE RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. (RFMH) WILL UNDERTAKE A MULTI-PRONGED APPROACH TO ADDRESS THE ISSUES OF OPIOID USE DISORDERS IN THE UNSERVED AND UNDERSERVED AREAS OF THE STATE. OASAS HAS IDENTIFIED HIGH NEED AREAS IN THE STATE AND THROUGH ITS EXISTING INFRASTRUCTURE WILL ENHANCE TREATMENT AND RECOVERY SERVICES. OASAS'S PROPOSAL IS TO DEVELOP CENTERS OF TREATMENT INNOVATION IN HIGH NEED AREAS WHICH WILL INCLUDE DEVELOPING TELE-HEALTH CAPACITY; INCREASING THE NUMBER OF PRESCRIBING PRACTITIONERS FOR MEDICATION ASSISTED TREATMENT VIA TRAINING AND MENTORING; HAVING CARE MANAGERS TO BRIDGE THE GAP BETWEEN BEHAVIORAL HEALTH AND PRIMARY CARE; USE OF LOCALLY PLACED PEER RECOVERY SUPPORT STAFF TO IMPROVE TREATMENT ENGAGEMENT AND RETENTION; ENHANCED CLINICAL STAFF; AND PROVIDING REENTRY SUPPORT FOR INDIVIDUALS BEING RELEASED FROM JAILS/CORRECTIONAL FACILITIES. OASAS WILL ALSO UTILIZE A MULTI-LEVEL PREVENTION APPROACHES INCLUDING DELIVERY OF EVIDENCE-BASED PREVENTION SERVICES TO UNDERSERVED, HARD-TO-REACH YOUTH AND OTHER AT RISKS POPULATIONS, FOSTER CARE SETTINGS AND PERMANENT SUPPORTIVE HOUSING; PROVIDE TRAINING AND DISTRIBUTION OF NALOXONE KITS; AND A TARGETED MEDIA CAMPAIGN. TO SUPPORT A GROWING RECOVERY COMMUNITY OASAS WILL DEVELOP A YOUTH AND YOUNG ADULT STATEWIDE RECOVERY NETWORK AND LOCAL COMMUNITY NETWORKS. OASAS LOOKS TO ESTABLISH A SOCIAL MEDIA CAMPAIGN THAT PROMOTES HEALTH, RECOVERY AND WELLNESS, ESTABLISH PEER SUPPORTS AND TO PROVIDE TECHNICAL ASSISTANCE AND SUPPORT TO LOCAL COMMUNITIES AND NETWORKS OF YOUNG PEOPLE ACROSS NEW YORK STATE.

NYS OPIOID STR PROJECT

ANTECEDENTS OF SUICIDAL BEHAVIOR RELATED NEUROBIOLOGY

NEUROBIOLOGY AND DYNAMICS OF ACTIVE SENSING

NOVEL MEDICATION APPROACHES FOR SUBSTANCE ABUSE

BREAKING THE CYCLE OF INTERGENERATIONAL DISADVANTAGE: NEURODEVELOPMENT AMONG PUERTO RICAN CHILDREN.

SHARED PHARMACOTHERAPEUTIC STRATEGIES FOR CANNABINOID & OPIOID USE DISORDERS

NEW YORK SERVICE OPPORTUNITIES TO ACCESS RECOVERY SUCCESSFULLY (NY SOARS)

EVALUATION OF SAFETY AND PHARMACOKINETICS OF NALTREXONE IMPLANT - NEW MEDICATION TREATMENT APPROACHES ARE NEEDED TO HELP ADDRESS THE SEVERE EPIDEMIC OF OPIOID USE DISORDER (OUD) AND OPIOID OVERDOSE DEATHS IN THE US. CURRENTLY AVAILABLE MEDICATIONS, METHADONE, BUPRENORPHINE, AND EXTENDED RELEASE INJECTION NALTREXONE (XR-NTX; TRADE NAME: VIVITROL), ARE HIGHLY EFFICACIOUS, BUT THEIR EFFECTIVENESS IN PRACTICE IS LIMITED BY POOR ADHERENCE, WITH MANY PATIENTS STOPPING TREATMENT PREMATURELY AND RELAPSING. THE GOAL OF THIS PROPOSAL IS TO DEVELOP AN INNOVATIVE LONG ACTING SUBCUTANEOUS IMPLANTED FORMULATION OF NALTREXONE, THE O’NEIL LONG-ACTING NALTREXONE IMPLANT (OLANI), TOWARDS FDA APPROVAL. EXPECTED TO PRODUCE NALTREXONE BLOOD LEVELS SUFFICIENT TO BLOCK THE EFFECTS OF OPIOIDS FOR 6 MONTHS AFTER IMPLANT, OLANI CIRCUMVENTS THE NEED FOR ADHERENCE TO MONTHLY INJECTIONS WITH XR-NTX, AND COULD REPRESENT AN IMPORTANT NEW ADDITION TO THE MEDICAL ARMAMENTARIUM FOR TREATMENT OF OUD. THE OLANI HAS BEEN IN DEVELOPMENT BY AN AUSTRALIAN COMPANY GO MEDICAL FOR 20 YEARS WITH SEVERAL PROTOTYPES EVALUATED IN CONTROLLED CLINICAL TRIALS AND USED CLINICALLY IN AUSTRALIA. THE CURRENT FORMULATION HAS HIGHER DRUG LOADING AND A BETTER RELEASE PROFILE AND IS MANUFACTURED IN A GMP FACILITY. IT HAS BEEN USED CLINICALLY IN OVER 800 PATIENTS, GIVING CONFIDENCE THAT THE PRODUCT CAN BE SUCCESSFULLY DEVELOPED IN THE US. GO MEDICAL AND THE CURRENT TEAM OF INVESTIGATORS MET WITH THE FDA TO CHART A DEVELOPMENT PATH TOWARDS A NEW DRUG APPLICATION (NDA) VIA THE 505 B(2) PATHWAY WITH VIVITROL AS A COMPARATOR PRODUCT. AN APPLICATION FOR AN IND (# 134996) IS UNDER REVIEW BY THE FDA. THIS PROPOSAL SEEKS NIDA’S SUPPORT UNDER THE UG3/UH3 MECHANISM TO CONDUCT THE STUDIES RECOMMENDED BY THE FDA FOR THE 505 B(2) PATHWAY TO APPROVAL. UNDER THE UG3 PHASE, STUDY 1 WILL EVALUATE LOCAL TISSUE TOXICITY OF OLANI IN A MINIPIG MODEL, AND STUDY 2 WILL GENERATE PILOT PHARMACOKINETIC (PK) DATA OF OLANI IN HEALTHY SUBJECTS IN ORDER TO DETERMINE POWER AND FINALIZE SAMPLE SIZE FOR A SUBSEQUENT BIOEQUIVALENCE (BE) STUDY AND TO SUPPORT FEASIBILITY AND TOLERABILITY. IF THERE ARE NO SAFETY CONCERNS AND NALTREXONE BLOOD LEVELS ARE ADEQUATE IN THE UG3 PHASE, THEN IN THE UH3 PHASE (STUDY 3) WILL BE FINALIZED IN CONSULTATION WITH NIDA AND FDA. STUDY 3 WILL COMPARE 6-MONTH PK OF OLANI VERSUS XR-NTX AS THE REFERENCE DRUG TO ESTABLISH BIOEQUIVALENCE (BE) IN TERMS OF NALTREXONE BLOOD LEVELS, SAFETY AND COMPARATIVE EFFECTIVENESS IN PATIENTS WITH OUD. PATIENTS WILL BE RANDOMIZED TO RECEIVE EITHER A SINGLE SUBCUTANEOUS IMPLANTATION OF 3.6G DOSE OF OLANI OR REPEAT DOSES OF VIVITROL 380 MG IM Q4 WEEKS FOR 24 WEEKS. PARTICIPANTS RANDOMIZED TO OLANI WILL BE OFFERED AN ADDITIONAL IMPLANT AT MONTH 6. WE HYPOTHESIZE THAT OLANI WILL HAVE A SYSTEMIC EXPOSURE (CMAX,CMIN,AUC0-180) AND MEC OF NALTREXONE BLOOD LEVELS COMPARABLE TO XR-NTX. IF OLANI IS SHOWN TO PROVIDE A SAFE, FEASIBLE AND EFFECTIVE METHOD OF DELIVERY OF NALTREXONE AT THERAPEUTIC LEVELS FOR AT LEAST 6 MONTHS, IT WOULD REPRESENT A MAJOR ADVANCE IN THE FIELD OF OUD TREATMENT, PROVIDING EFFECTIVE LONG TERM RELAPSE-PREVENTION TREATMENT TO INDIVIDUALS WITH OUD.

MENTAL HEALTH AND RISK IN HIV+ YOUTH AND SEROREVERTERS

NYS SYSTEM OF CARE

PREVENTION FIRST - NY!

OPTIMIZING AND PERSONALIZING INTERVENTIONS FOR SCHIZOPHRENIA ACROSS THE LIFESPAN (OPAL)

NYSBIRT PROJECT

NYS OASAS PIPBHC PROJECT

NOVEL COGNITIVE AND FUNCTIONAL MEASURE FOR ALZHEIMER'S DISEASE PREVENTION TRIALS

STRUCTURE AND FUNCTION OF DOPAMINE RECEPTORS

SEROTONERGIC MODULATION OF BRAIN DEVELOPMENT: GENETIC AND PHARMACOLOGIC INFLUENC

DOPAMINE DYSFUNCTION IN SCHIZOPHRENIA

LEVERAGING SOCIAL NETWORKS TO INCREASE COVID-19 TESTING UPTAKE: A COMPARISON OF CREDIBLE MESSENGER AND CHAIN REFERRAL RECRUITMENT APPROACHES

CHILDREN AT HIGH AND AT LOW RISK FOR DEPRESSION

PHASE 1A/1B CLINICAL TRIALS OF MULTIVALENT OPIOID VACCINE COMPONENTS

NYSBIRT

ADDRESSING THE YOUTH MENTAL HEALTH CRISIS THROUGH COLLABORATIVE CARE EXPANSION IN NEW YORK STATE - THE NEW YORK STATE OFFICE OF MENTAL HEALTH (NYS OMH) HAS LED THE NATION IN ADOPTION AND SCALE OF THE PSYCHIATRIC COLLABORATIVE CARE MODEL (COCM) AND SEEKS TO BUILD ON THAT SUCCESS BY EXPANDING THE NUMBER OF YOUTH-SERVING PRIMARY CARE PRACTICES PARTICIPATING IN THE PROGRAM TO ADDRESS THE YOUTH MENTAL HEALTH CRISIS AND ADVANCE HEALTH EQUITY. THIS INITIATIVE WILL ADDRESS MENTAL AND BEHAVIORAL HEALTH PROBLEMS AMONG CHILDREN AND ADOLESCENTS WITH CO-OCCURRING SERIOUS EMOTIONAL DISTURBANCE (SED) AND PHYSICAL HEALTH CONDITIONS OR CHRONIC DISEASE, SUCH AS DEPRESSION, ANXIETY, ADHD, SUBSTANCE USE DISORDERS, AND SUICIDAL THOUGHTS AND BEHAVIORS, BY PROVIDING INTEGRATED BEHAVIORAL HEALTH SERVICES. AN EXPLICIT GOAL OF THE PROJECT IS TO ENSURE EQUITABLE ACCESS OF SERVICES TO POPULATIONS WHO HAVE HISTORICALLY LACKED ACCESS, INCLUDING BIPOC, LGBTQ+, AND RURAL YOUTH. THIS PROJECT WILL BE IMPLEMENTED STATEWIDE IN NEW YORK, THE FOURTH MOST POPULOUS STATE IN THE COUNTRY. PARTICIPATING PROVIDERS WILL REPRESENT THE DIVERSITY OF NYS, INCLUDING BOTH URBAN AND RURAL PRIMARY CARE SETTINGS, LARGE PUBLIC HOSPITAL CLINICS, AND SMALL PRIVATE PRACTICES SERVING OVER 3500 YOUTH ACROSS 15 SITES. THE HALLMARKS OF THE NYS COCM IMPLEMENTATION APPROACH ARE 1) EXTENSIVE TECHNICAL ASSISTANCE AND SUPPORT FOR PARTICIPATING PRACTICES AND 2) ROBUST PROCESS AND OUTCOMES METRICS TO ENSURE DELIVERY OF CARE THAT MAKES A DIFFERENCE IN THE LIVES OF YOUTH AND THEIR FAMILIES. IN ADDITION TO TECHNICAL ASSISTANCE AND SUPPORT FOR THE ADOPTION OF COCM, PARTICIPATING PRACTICES WILL ALSO RECEIVE TRAINING IN SUICIDE PREVENTION BEST PRACTICES. A SIGNIFICANT PORTION OF AWARD FUNDS WILL BE AIMED AT OVERCOMING WORKFORCE SHORTAGES, AN IDENTIFIED BARRIER, AND SUPPORTING DEVELOPMENT OF A SUSTAINABLE MODEL BY THE END OF THE FIVE-YEAR PROJECT.

PHASE 1A/1B CLINICAL TRIALS OF MULTIVALENT OPIOID VACCINE COMPONENTS - PROJECT SUMMARY CURRENTLY, ABUSE OF PRESCRIPTION OPIOID ANALGESICS AND HEROIN IS A PERVASIVE PROBLEM IN THE U.S. ALTHOUGH SEVERAL MEDICATIONS, INCLUDING METHADONE, BUPRENORPHINE, AND NALTREXONE, ARE AVAILABLE AND EFFECTIVE IN TREATING OPIOID USE DISORDER (OUD), LONG-TERM RELAPSE RATES REMAIN HIGH. THE CURRENT STUDIES ARE DESIGNED TO EXAMINE A NOVEL APPROACH TO TREATING OUD, NAMELY USE OF A VACCINE (OXY-KLH) TARGETED AGAINST OXYCODONE, ONE OF THE MOST COMMONLY ABUSED PRESCRIPTION OPIOIDS, AND A VACCINE (M-KLH) TARGETED AGAINST HEROIN/MORPHINE. ULTIMATELY, A BIVALENT VACCINE (OXY-KLH AND M-KLH) WILL BE DEVELOPED THAT WILL TARGET OXYCODONE AND HEROIN. THE LONG-TERM GOAL OF THIS RESEARCH IS TO DEVELOP A MULTIVALENT VACCINE DIRECTED AGAINST OXYCODONE, HEROIN, AND OTHER RELEVANT OPIOIDS. HOWEVER, DURING OUR PRE-IND MEETING, THE FDA/CBER ASKED THAT WE STUDY EACH VACCINE SEPARATELY BEFORE MOVING FORWARD WITH DEVELOPMENT OF THE BIVALENT VACCINE. THE CURRENT APPLICATION PROPOSES A PHASE 1A/1B STUDY DESIGNED TO EVALUATE THE SAFETY (AIM 1), IMMUNOGENICITY (AIM 2), AND PRELIMINARY EFFICACY (AIM 3) OF OXY-KLH DURING THE UG3 PHASE OF THE GRANT PERIOD (STUDY 1) AND A SIMILAR PHASE 1A/1B STUDY OF M-KLH DURING THE UH3 PHASE OF THE GRANT PERIOD (STUDY 2). TRANSITION TO THE UH3 PHASE WILL BE DETERMINED AFTER SAFETY, IMMUNOGENICITY, AND PRELIMINARY EFFICACY ANALYSES HAVE BEEN PERFORMED FOR THE OXY-KLH VACCINE. OVERALL, THE PROPOSED STUDIES WILL PROVIDE A GREAT DEAL OF INFORMATION ABOUT THE SAFETY AND POTENTIAL EFFICACY OF THE VACCINES IN REDUCING THE ABUSE LIABILITY OF OPIOIDS, WHICH WILL BE ADMINISTERED IN A CONTROLLED LABORATORY SETTING. IF THE OUTCOMES OF THE PROPOSED STUDIES WITH OXY-KLH AND M- KLH ARE FAVORABLE, WE WILL PROCEED WITH DEVELOPMENT OF THE BIVALENT VACCINE (OXY-KLH PLUS M-KLH).

EARLY CORTICAL PROCESSING IN SCHIZOPHRENIA

HUMAN TRIAL OF ALLOSTERIC MODULATOR ALPHA7 NICOTINIC RECEPTORS IN SCHIZOPHRENIA

ADAPTING COORDINATED SPECIALTY CARE IN THE POST COVID-19 ERA

NEW YORK SPF-PFS PROJECT

NYS PARTNERSHIP FOR SUCCESS 2022 - THE NYS SPF-PFS 2022'S GOAL IS TO REDUCE BEHAVIORAL HEALTH DISPARITIES AMONG OUR MOST VULNERABLE POPULATIONS BY STRENGTHENING THE STATE AND LOCAL COMMUNITY'S CAPACITY TO BUILD AND SUSTAIN CULTURALLY APPROPRIATE PREVENTION SERVICES IN HIGH-RISK UNDERSERVED I.E. BLACK, INDIGENOUS, AND PEOPLE OF COLOR (BIPOC); LESBIAN, GAY, BISEXUAL, TRANSGENDER PLUS (LGBT+); AND RURAL COMMUNITIES. WE INTEND TO INCREASE ACCESS TO QUALITY PREVENTION SERVICES WITHIN OUR MOST HIGH-RISK COMMUNITIES USING THE DATA-DRIVEN STRATEGIC PREVENTION FRAMEWORK (SPF) TO DEVELOP AND TO WIDELY DISSEMINATE CULTURALLY RESPONSIVE PREVENTION STRATEGIES ADDRESSING UNDERAGE AND PROBLEM ALCOHOL AND CANNABIS USE. USING STATE AND LOCAL DATA TO IDENTIFY AREAS OF HIGHEST PREVENTION NEED, OASAS WILL FUND SIX HIGH-CAPACITY COMMUNITY COALITIONS BASED ON THEIR ABILITY TO REACH VULNERABLE, HIGH-RISK, OR UNDERSERVED COMMUNITIES SUCH AS BIPOC, LGBT+, AND RURAL COMMUNITIES. THE SELECTED COALITIONS WILL RECEIVE TARGETED TRAINING AND TECHNICAL ASSISTANCE TO IMPLEMENT THE SPF PROCESS AND TO ADAPT ENVIRONMENTAL CHANGE STRATEGIES, INCLUDING MEDIA, POLICY, AND COMPLIANCE COMPONENTS, TO REDUCE OR DELAY UNDERAGE ALCOHOL/CANNABIS USE AND REDUCE ADULT PROBLEM ALCOHOL/CANNABIS USE. EACH COALITION WILL BUILD LOCAL RESOURCES TO DEVELOP AND EVALUATE CULTURALLY RESPONSIVE MESSAGING TO PREVENT THE ONSET AND REDUCE THE PROGRESSION OF SUBSTANCE MISUSE AND ITS RELATED HEALTH PROBLEMS WHILE STRENGTHENING COMMUNITY AND STATE LEVEL PREVENTION CAPACITY TO ENGAGE HEALTH DISPARATE POPULATIONS. USING A MIX OF EVIDENCED-BASED PROGRAMS, POLICIES AND PRACTICES, EACH COALITION WILL FOCUS ON CREATING POPULATION CHANGE AND SUSTAINABLE PREVENTION. OUR MEASURABLE OBJECTIVES OUTLINED BELOW ARE DERIVED FROM OUTCOMES ASSOCIATED WITH NYS OASAS'S PREVIOUS IMPLEMENTATION OF SAMHSA'S STATE INCENTIVE GRANT 1999-2003, THE NYS SPF-SIG 2009, AND NYS PFS 2014 WHICH FUNDED ENVIRONMENTAL STRATEGY COALITION WORK: 1. INCREASE AWARENESS WITHIN HIGH-RISK UNDERSERVED COMMUNITIES (E.G. BIPOC, LGBT+, AND RURAL) OF THE DANGERS OF UNDERAGE PROBLEM ALCOHOL AND CANNABIS USE THROUGH CULTURALLY RESPONSIVE PREVENTION MESSAGING. 2. PREVENT THE ONSET AND REDUCE THE PROGRESSION OF PROBLEM ALCOHOL/CANNABIS USE IN HIGH-RISK UNDERSERVED COMMUNITIES (E.G. BIPOC, LGBT+ AND RURAL) BY IMPLEMENTING ENVIRONMENTAL CHANGE STRATEGIES (ECS). 3. INCREASE CAPACITY AND INFRASTRUCTURE FOR COLLABORATIONS TO IMPLEMENT CULTURALLY RESPONSIVE, DATA-DRIVEN PREVENTION FOR HIGH-RISK UNDERSERVED COMMUNITIES. THIS INITIATIVE'S NEEDS, RESOURCE, AND CAPACITY ASSESSMENTS WILL SERVE AS A FOUNDATION FOR OASAS'S STATEWIDE COMMUNITY HEALTH ASSESSMENT (CHA) AND A STATEWIDE COMMUNITY HEALTH IMPROVEMENT PLAN (CHIP) FOR SUBSTANCE USE PREVENTION TO ADVANCE BEHAVIORAL HEALTH EQUITY ACROSS NYS'S DIVERSE COMMUNITIES. THE CHA WILL IDENTIFY KEY SUBSTANCE USE AND MISUSE PREVENTION PRIORITIES, GAPS IN SERVICES, AND BEHAVIORAL HEALTH DISPARITIES THROUGH A SYSTEMATIC, COMPREHENSIVE DATA COLLECTION PROCESS, ANALYSIS, AND DISSEMINATION. THE CHIP WILL ACT AS A STATE AND LOCAL FRAMEWORK FOR LONG-TERM SUBSTANCE USE/MISUSE PREVENTION. THE PLAN WILL IDENTIFY PRIORITY COMMUNITIES AND OFFER BEST PRACTICE GUIDELINES TO BUILD CAPACITY FOR EFFECTIVE RESPONSIVE PREVENTION STRATEGIES GLEANED FROM NYS PFS 2022. BOTH THE CHA AND CHIP WILL BE A DATA-DRIVEN APPROACH TO ADDRESS THE LASTING HEALTH CONSEQUENCES ASSOCIATED WITH SUBSTANCE USE AND MISUSE SPECIFICALLY IN HEALTH DISPARATE POPULATIONS.

EVALUATION OF SAFETY AND PHARMACOKINETICS OF NALTREXONE IMPLANT

NYS YOUTH AND FAMILIES ACHIEVE

NYS YOUTH AND FAMILIES ACHIEVE

NYS OASAS MAT-PDOA

PRIDE SSA - PARTNERSHIPS IN RESEARCH TO IMPLEMENT AND DISSEMINATE SUSTAINABLE AND SCALABLE EVIDENCE BASED PRACTICES IN SUB-SAHARAN AFRICA

EFFECT OF MAJOR DEPRESSION AND ANTIDEPRESSANTS ON HUMAN NEUROGENESIS

SEROTONIN AND THE MODULATION OF BRAIN DEVELOPMENT

CORTICAL AND THALAMIC MECHANISMS OF SELECTIVE AUDITORY ATTENTION

1/7 CLOZAPINE FOR THE PREVENTION OF VIOLENCE IN SCHIZOPHRENIA: A RANDOMIZED CLINICAL TRIAL - WHILE MOST PEOPLE WITH PSYCHOSIS ARE NOT DANGEROUS AND MOST VIOLENCE IS COMMITTED BY NON-PSYCHOTIC PEOPLE, PEOPLE WITH PSYCHOTIC DISORDERS ARE AT INCREASED RISK FOR VIOLENCE, AND VIOLENCE IS ASSOCIATED WITH WORSE OUTCOMES AND INCREASED STIGMA. THEREFORE, DECREASING VIOLENCE RISK IN PSYCHOSIS IS CLINICALLY RELEVANT AND HAS IMPORTANT PUBLIC HEALTH IMPLICATIONS. SEVERAL CLINICAL STUDIES SUGGEST THAT CLOZAPINE IS SUPERIOR TO OTHER ANTIPSYCHOTIC MEDICATIONS IN REDUCING VIOLENCE OR AGGRESSION. HOWEVER, THERE WERE NUMEROUS LIMITATIONS OF THESE STUDIES INCLUDING THAT MOST OF THEM WERE OBSERVATIONAL AND NON-RANDOMIZED, INCLUDED SMALL SAMPLE SIZES, OR FOCUSED ON HOSTILITY, NON-PHYSICAL AGGRESSION, OR SELF-HARM, RATHER THAN VIOLENT ACTS. FURTHER, THE MAJORITY OF THESE TRIALS WERE NOT GENERALIZABLE TO OUTPATIENT, COMMUNITY SETTINGS. NO LARGE EFFECTIVENESS STUDY HAS EXAMINED THE EFFECTS OF CLOZAPINE ON VIOLENT BEHAVIOR IN COMMUNITY SETTINGS. WE PROPOSE A RANDOMIZED, PARALLEL-GROUP, 24-WEEK, OPEN-LABEL, SINGLE (RATER)-BLIND, 7-SITE CLINICAL TRIAL TO EXAMINE THE EFFECTS OF TREATMENT WITH CLOZAPINE VS. TREATMENT AS USUAL (TAU) ON THE RISK OF VIOLENT ACTS IN 280 INDIVIDUALS WITH SCHIZOPHRENIA AT HIGH RISK FOR VIOLENCE. THIS TRIAL WILL BE A COLLABORATION OF 7 SITES, COORDINATED BY THE NEW YORK STATE PSYCHIATRIC INSTITUTE. THE 6 ADDITIONAL COLLABORATING SITES CONTRIBUTE UNIQUE EXPERTISE AND WILL ENSURE AN ADEQUATE SAMPLE SIZE FOR THIS TRIAL. OUR PRIMARY EFFECTIVENESS OUTCOME IS TIME TO VIOLENT ACTS AS MEASURED BY THE MACARTHUR COMMUNITY VIOLENCE INTERVIEW (MCVI). WE WILL ALSO EXPLORE THE EFFECTS OF CLOZAPINE ON THE POINT SUBTRACTION AGGRESSION PARADIGM. WHILE MANY FACTORS MAY CONTRIBUTE TO VIOLENT BEHAVIOR IN INDIVIDUALS WITH SCHIZOPHRENIA, INCLUDING POSITIVE SYMPTOMS, PSYCHOPATHY, IMPULSIVITY, AND SUBSTANCE USE, EVIDENCE SUGGESTS THAT THE FINAL COMMON PATHWAY FOR MANY OF THESE DISPARATE CAUSAL INFLUENCES LIKELY RUNS THROUGH BEHAVIORS CAPTURED BY THE EXCITEMENT FACTOR OF THE POSITIVE AND NEGATIVE SYNDROME SCALE (I.E., A COMPOSITE OF THE SCORES OF EXCITEMENT, UNCOOPERATIVENESS, POOR IMPULSE CONTROL, AND HOSTILITY). IMPORTANTLY, OUR TARGET (THE EXCITEMENT FACTOR OF THE PANSS) HAS BEEN VALIDATED TO MEASURE EXCITEMENT-LIKE SYMPTOMS IN CLINICAL TRIALS IN SCHIZOPHRENIA, IS SENSITIVE TO TREATMENT, HAS BEEN LINKED TO THE NEUROBIOLOGY OF VIOLENCE IN SPECTROSCOPY AND PET STUDIES, AND DIFFERENTIATES CLOZAPINE FROM OTHER ANTIPSYCHOTIC DRUGS. WE WILL ALSO EXPLORE THE EFFECTS OF CLOZAPINE VS. TAU ON POSITIVE SYMPTOMS (E.G., PERSECUTORY DELUSIONS) AND ALCOHOL AND SUBSTANCE USE, AND HOW THESE EFFECTS INFLUENCE THE RISK FOR VIOLENT ACTS. TO ENHANCE THE SAFE IMPLEMENTATION OF THIS STUDY IN THIS VULNERABLE POPULATION AT RISK OF VIOLENT BEHAVIORS, WE WILL IMPLEMENT CLINICAL SAFETY AND TREATMENT ENGAGEMENT PROTOCOLS THAT RELY UPON STANDARD PERSONNEL AND THAT WILL BE READILY GENERALIZABLE. THIS TRIAL WILL PROVIDE GUIDANCE ON THE USE OF CLOZAPINE FOR VIOLENCE IN COMMUNITY SETTINGS AND WILL DEFINITIVELY TEST HYPOTHESES REGARDING MECHANISMS OF ITS ANTI-VIOLENCE EFFECTS. THE RESULTS WILL BE IMMEDIATELY RELEVANT TO PRACTICE AND WILL IMPACT PUBLIC HEALTH BECAUSE THERE IS CURRENTLY NO STANDARD APPROACH FOR THE TREATMENT OF VIOLENCE IN SCHIZOPHRENIA.

MARIJUANA RELAPSE: INFLUENCE OF TOBACCO CESSATION AND VARENICLINE

DEFINING NEURONAL CIRCUITS AND CELLULAR PROCESSES UNDERLYING RESTING FMRI SIGNALS

MEDIUM SPINY NEURON EXCITABILITY AND MOTIVATION

HEALTH AND JUSTICE: A CONTINUUM OF CARE FOR HIV AND SU FOR JUSTICE-INVOLVED YOUTH

THE ROLE OF CA2 IN EPILEPSY AND SOCIAL COMORBIDITY

CAPITAL CONNECT - EACH YEAR, APPROXIMATELY 1,700 NEW YORKERS DIE BY SUICIDE, RANKING NEW YORK STATE (NYS) 6TH IN THE NATION FOR OVERALL SUICIDE BURDEN. BETWEEN 2000 AND 2020, THE SUICIDE RATE IN NYS INCREASED 35.6%, FROM 5.9 TO 8.0 PER 100,000 POPULATION, SURPASSING ANNUAL DEATH RATES BY HOMICIDE AND MOTOR VEHICLE ACCIDENTS. IN 2019 THERE WERE AN ESTIMATED 42,600 SUICIDE ATTEMPTS AMONG NEW YORKERS LEADING TO 22,430 HOSPITALIZATIONS AND EMERGENCY DEPARTMENT VISITS. FROM 2015-2019, IT IS ESTIMATED THAT 565,000 NEW YORKERS HAD SUICIDAL THOUGHTS ANNUALLY. THE SCALE OF THE PROBLEM IS GREATLY EXPANDED BY THE GRIEF OF FRIENDS AND FAMILY MEMBERS OF THOSE WHO ATTEMPTED OR DIED BY SUICIDE. COVID-19’S ONGOING IMPACT IN NYS ADDS TO THE PROBLEM. AS OF MAY 21, 2022, THERE HAVE BEEN 5,346,809 INFECTIONS AND 55,917 DEATHS RESULTING FROM COVID-19. RESEARCH CONDUCTED DURING THE PANDEMIC REVEALS SIGNS OF BROAD INCREASES IN MENTAL DISTRESS ACROSS THE POPULACE, BUT PARTICULARLY AMONG YOUTH. HOWEVER, COVID-19’S FULL IMPACT ON MENTAL HEALTH AND SUICIDE RISK IS NOT WELL UNDERSTOOD. CONTINUED MONITORING ON SUICIDE RISK IS IMPERATIVE. THE NYS OFFICE OF MENTAL HEALTH (OMH) REQUESTS FUNDING TO IMPLEMENT A COMPREHENSIVE, MULTI-TIERED APPROACH TO SUICIDE PREVENTION IN ALBANY, RENSSELAER, SARATOGA, AND SCHENECTADY COUNTIES, A FOUR-COUNTY REGION IN THE HEART OF THE NEW YORK’S CAPITAL DISTRICT WHERE SUICIDE MORBIDITY AND MORTALITY EXCEED STATE AVERAGES. THE PROPOSED INITIATIVE IS CALLED CAPITAL CONNECT, AS IT AIMS TO PROVIDE CRITICAL SUPPORT AND FOSTER CONNECTION AMONG THE MOST AT-RISK. OMH PROPOSES TARGETING TWO POPULATIONS FOUND TO BE AT PARTICULARLY HIGH-RISK BASED ON NYS SURVEILLANCE DATA: ADOLESCENT GIRLS (AGED 10-19) AND WORKING-AGED MEN (AGED 25-64). OMH WILL UTILIZE A DATA-DRIVEN APPROACH FOR SUICIDE PREVENTION WITH THE PRIMARY GOAL OF REDUCING SUICIDE MORBIDITY AND MORTALITY IN THESE DISPROPORTIONALLY AFFECTED POPULATIONS BY 10% OVER THE FIVE-YEAR GRANT PERIOD. SECONDARY GOALS INCLUDE INCREASING ACCESS TO EVIDENCE-BASED SUICIDE PREVENTION INTERVENTIONS WITH AN ASSOCIATED REDUCTION IN DISPARITIES WITHIN THE CATCHMENT AREA. THE PROPOSED APPROACH WILL BE RIGOROUSLY EVALUATED WITH A FOCUS ON CONTINUOUS QUALITY IMPROVEMENT AND SUSTAINED IMPACT. IN PURSUING IMPLEMENTATION OF THE PROPOSED PROJECT IN THE FOUR-COUNTY JURISDICTION, AN EXPLICIT AIM IS TO TEST THE FEASIBILITY OF A MODEL WITH STATEWIDE SCALING POTENTIAL. LED BY THE OMH SUICIDE PREVENTION CENTER OF NEW YORK IN CLOSE PARTNERSHIP WITH THE NYS DEPARTMENT OF HEALTH, THE PROJECT WILL LEVERAGE AND STRENGTHEN A MULTI-SECTORAL PARTNERSHIP PLAN THAT INCLUDES PARTNERS IN STATE AND LOCAL GOVERNMENT, ACADEMIA, JUVENILE JUSTICE, SCHOOLS, LOCAL HOSPITALS AND PRIMARY CARE CLINICS, CRISIS SERVICES, ADVOCATES, THE LIVED EXPERIENCE COMMUNITY, AND A SUICIDE PREVENTION DIGITAL TECHNOLOGY START-UP FIRM. REGULARLY REVIEWING THE LATEST SURVEILLANCE DATA TO GUIDE EFFORTS, PARTNERS WILL IMPLEMENT NINE SEPARATE EMPIRICALLY SUPPORTED APPROACHES TO CARRY OUT A COMPREHENSIVE APPROACH TO SUICIDE PREVENTION.

PROMOTING HOPE AND OPPORTUNITIES FOR YOUTH WITH EARLY PSYCHOSIS

SBIRT COMMUNITY BASED OUTREACH - THE NEW YORK SBIRT COMMUNITY OUTREACH PROJECT WILL IMPLEMENT AND EVALUATE AN INNOVATIVE, CULTURALLY RESPONSIVE MODEL TO DELIVER SBIRT SERVICES TO UNDERSERVED ADOLESCENT AND ADULT POPULATIONS HISTORICALLY UNLIKELY TO ACCESS TREATMENT SERVICES (SEXUAL MINORITY [LGBT+]; ECONOMICALLY DISADVANTAGED; LATINX IMMIGRANT; NATIVE AMERICAN; AND RURAL) IN 4 AREAS OF THE STATE: NEW YORK CITY (NYC); FIVE TOWNS, LONG ISLAND; FINGER LAKES; AND ST. REGIS MOHAWK RESERVATION. SBIRT WILL BE DELIVERED WITHIN COMMUNITY-BASED SETTINGS BY TRAINED OUTREACH WORKERS FROM THE TARGETED POPULATION. THE RECOMMENDED SCREENING TOOLS TO IDENTIFY SUBSTANCE USE (CRAFFT+N 2.1 FOR ADOLESCENTS; AUDIT AND DAST-10 FOR ADULTS) AND SUICIDE (C-SSRS FOR ADOLESCENTS AND ADULTS) RISK. IF SCREENED POSITIVE FOR SUBSTANCE USE RISK, THE INDIVIDUAL WILL RECEIVE BRIEF INTERVENTION (BI) WITH A BRIEF NEGOTIATED INTERVIEW (BNI) USING MOTIVATIONAL INTERVIEWING (MI) TECHNIQUES. IF SCREENED POSITIVE FOR SUICIDE RISK, THE SAFETY PLANNING INTERVENTION (SPI) WITH FOLLOW-UP WILL BE USED. IF BRIEF TREATMENT (I.E., COGNITIVE BEHAVIORAL THERAPY) OR SPECIALTY TREATMENT (I.E., MEDICATION ASSISTED TREATMENT [MAT] IS WARRANTED, THE ACTIVE REFERRAL TO TREATMENT (ART) MODEL WILL BE FOLLOWED TO ENSURE HOT HANDOFFS TO SUBSTANCE USE DISORDER (SUD), MAT, AND/OR MENTAL HEALTH MH PROVIDERS. PRE-ESTABLISHED AND CONTINUED COLLABORATIONS WILL ASSIST IN CARE TRANSITIONS. PROJECT GOALS ARE TO: (1) DEVELOP, REFINE, AND PILOT AND INNOVATIVE SBIRT COMMUNITY OUTREACH MODEL TO REDUCES ACCESS BARRIERS AND INCREASE SERVICE USE AMONG HIGH-RISK POPULATIONS HESITANT TO SEEK SERVICES. OASAS WILL USE FOCUS GROUPS AND KEY INFORMANT INTERVIEW DATA TO DESIGN A CULTURALLY APPROPRIATE MODEL, TRAIN SITES TO DELIVER IT, PILOT IT, AND THEN REFINE IT BASED ON FEEDBACK. (2) DELIVER THE REFINED MODEL IN AT LEAST 12 SEPARATE COMMUNITY SETTINGS DOCUMENTING CULTURAL MODIFICATIONS TO INCREASE SERVICE ACCESS, DECREASE HEALTH DISPARITIES, SUBSTANCE USE, RISK BEHAVIORS, AND SUICIDE RISK IN NYC, FIVE TOWNS, THE FINGER LAKES, AND ST. REGIS MOHAWK RESERVATION. 5,000 SCREENINGS, 1,000 BIS, AND 350 RTS WILL BE DELIVERED PER YEAR. (3) DISSEMINATE OUR MODEL TO OTHER HIGH-RISK COMMUNITIES AND SUSTAIN IT. IN YEARS 3-5, AT LEAST 3 MORE PROVIDERS WILL IMPLEMENT THE SBIRT MODEL AND BECOME CERTIFIED CHILDREN AND FAMILY TREATMENT SERVICE PROVIDERS. IN YEARS 2-5, NEW PROVIDERS WILL BE TRAINED, TRAINING MATERIALS WILL BE UPDATED AND STATE TRAINING CAPACITY INCREASED. IN YEARS 4-5, TRAINING OF THE TRAINER (TOT) WILL BUILD CAPACITY TO SUSTAIN OUR SBIRT MODEL FOLLOWING THE GRANT. (4) EVALUATE PROCESSES AND OUTCOMES OF THE SBIRT OUTREACH MODEL AND IMPACT ON SERVICE UTILIZATION, SUBSTANCE USE, AND SUICIDE RISK. PROJECT SITES WILL COLLECT DATA BY MONTH 4 AND TRACK THE NUMBER OF SCREENS, BIS, RTS, AND SUICIDE SPECIFIC SCREENINGS AND INTERVENTIONS. BETWEEN BASELINE AND 6-MONTH FOLLOW-UP, OASAS WILL ASSESS CHANGES IN SUBSTANCE USE RESULTING FROM BI, AND STARTING IN YEAR 2, OASAS WILL ASSESS INCREASED IDENTIFICATION OF SUBSTANCE MISUSE RISK AND CONNECTION TO SUD TREATMENT AMONG THE TARGET POPULATIONS AS COMPARED TO A SIMILAR GROUP OF INDIVIDUALS RECEIVING ONLY SCREENING AND REFERRAL.

USE OF ARV DRUG LEVELS IN DBS TO ASSESS AND MANAGE ART ADHERENCE IN SOUTH AFRICA

NEW TECHNOLOGIES TO IDENTIFY MOLECULAR REGULATORS OF THE HUMAN HIPPOCAMPUS NEUROGENIC NICHE IN HEALTHY AGING AND ALZHEIMER'S DISEASE - THE HIPPOCAMPUS NEUROGENIC NICHE (HNN) GENERATES NEW NEURONS IN MAMMALS, BUT IT IS UNCLEAR IF THIS IS HAPPENING IN HUMANS. ADULT HIPPOCAMPAL NEUROGENESIS IS NECESSARY TO MAINTAIN INTACT COGNITIVE AND EMOTIONAL FUNCTIONS REGULATED BY THE HIPPOCAMPUS. MARKERS OF IMMATURITY HAVE BEEN DETECTED IN NEURONAL CELLS OF THE HNN BUT IT IS STILL UNCLEAR IF THEY REPRESENT ADULT-BORN NEURONS, OR NEURONAL CELLS THAT HAVE MAINTAINED THEIR IMMATURITY SINCE BIRTH. WE FOUND THAT THE NUMBER OF NEURAL PROGENITOR CELLS (NPCS) AND IMMATURE NEURONS WAS STABLE THROUGHOUT THE EIGHTH DECADE OF LIFE IN NORMAL AGING (NA) SUBJECTS, BUT ANGIOGENESIS AND NEUROPLASTICITY WERE DECREASED IN OLDER PEOPLE. OTHER GROUPS HAVE SUPPORTED OUR FINDINGS, WHILE SOME COULD NOT DETECT IMMATURE NEURONAL CELLS IN HUMAN HIPPOCAMPUS. MOREOVER, IN AGING MICE, MORE NPCS DIFFERENTIATE INTO GLIA RATHER THAN NEURONS, COMPARED TO YOUNGER ANIMALS, BUT WE DO NOT KNOW IF THIS HAPPENS IN HUMANS. ADULT NEUROGENESIS IS LOWER IN ALZHEIMER’S DISEASE (AD) AND IT IS UNKNOWN IF THIS IS BECAUSE MORE NPCS DIFFERENTIATE INTO GLIA OR THROUGH OTHER MECHANISMS. THESE GAPS IN KNOWLEDGE WARRANT THE USE OF NEW TECHNOLOGIES TO INVESTIGATE CELLULAR LINEAGES IN THE HUMAN HNN, AND MOLECULAR REGULATORS OF NPCS PROLIFERATION, CELL FATE, DIFFERENTIATION, MATURATION AND SURVIVAL. THIS PROJECT AIMS TO IDENTIFY DIFFERENTIALLY EXPRESSED PROTEINS (DEPS) AND GENES (DEGS) IN THE HUMAN HNN, AT THE REGIONAL AND SINGLE CELL LEVEL, COMPARING NA AND AD. WE WILL APPLY OUR PIPELINE USING HIGH RESOLUTION MASS SPECTROMETRY FOR PROTEOMICS ANALYSIS, AND SINGLE NUCLEI (SN) RNA AND ATAC (ASSAY FOR TRANSPOSASE- ACCESSIBLE CHROMATIN) SEQUENCING (SEQ), TO IDENTIFY GENE EXPRESSION AND EPIGENETIC CHANGES. IN SLIDE-MOUNTED HIPPOCAMPUS TISSUE, WE WILL APPLY VISIUM (10X GENOMICS) AND OUR CUSTOM-MADE SPATIAL TRANSCRIPTOMIC TECHNOLOGY FOR ANATOMICAL CO-MAPPING OF CELL-TYPE SPECIFIC MRNAS AND PROTEINS (DBIT-SEQ). NOVEL COMPUTATIONAL APPROACHES WILL IDENTIFY NEUROGENESIS REGULATORS IN THE HUMAN HNN THAT CAN BE TESTED IN CELLULAR OR ANIMAL MODELS. FINDINGS OBTAINED WITH THESE “OMICS” APPROACHES WILL BE VALIDATED USING HIGHPLEX RNASCOPE® (ADCBIO) AND IMMUNOFLUORESCENCE, AND QPCR, WESTERN BLOTS, AND ELISA ASSAYS, TO VISUALIZE AND QUANTIFY DEP AND DEG EXPRESSION AT THE SINGLE CELL AND REGIONAL LEVEL. OUR RIGOROUS BRAIN COLLECTION METHODS ASSURE TISSUE QUALITY, UNIFORM PROCESSING, USE OF TOXICOLOGY AND NEUROPATHOLOGY, AND STRICT CLINICAL INCLUSION/EXCLUSION CRITERIA. GROUPS INCLUDE: NA SUBJECTS (N=100), BRAAK STAGE 0-1, AGE 14-99 YRS., 40 OF WHICH (60 YEARS OF AGE AND OLDER) ARE MATCHED (BY AGE, SEX AND POSTMORTEM INTERVAL BETWEEN DEATH AND BRAIN COLLECTION) WITH 40 AD CASES (FROM THE COLUMBIA TAUB INSTITUTE COLLECTION), BRAAK STAGE 1 THROUGH 4. AIMS: 1. IDENTIFY HNN DEPS ASSOCIATED WITH NA AND AD. 2. IDENTIFY DEGS IN IMMATURE AND MATURE NEURONAL AND GLIAL CELL POPULATIONS OF THE DG IN NA AND AD SUBJECTS, USING SN-RNA AND SN-ATAC-SEQ (10X GENOMICS). 3. DETERMINE THE ANATOMICAL LOCALIZATION OF CELL EXPRESSING DEGS AND DEPS ASSOCIATED WITH NA AND AD, USING VISIUM AND DBIT-SEQ. 4. TEST CORRELATIONS BETWEEN DEPS AND DEGS, AND NUMBERS OF NPCS AND IMMATURE NEURONS AND GLIA IN NA AND AD.

COGNITIVE CONTROL IN CHILDREN OF SUD PARENTS: A LONGITUDINAL MULTIMODAL MRI STUDY

ASTROCYTES AS THE INTEGRATORS OF NEUROMODULATOR SIGNALS - THIS TRANSFORMATIVE AWARD APPLICATION IS DESIGNED TO TEST AN INTEGRATIVE HYPOTHESIS ABOUT ASTROCYTE FUNCTION ACROSS THE BRAIN WHILE EXTENDING THE CURRENT LIMITS OF STATE-OF-THE-ART TECHNOLOGIES IN CELLULAR IMAGING AND SPATIAL TRANSCRIPTOMICS. THE TEAM OF INVESTIGATORS WITH CELLULAR, MOLECULAR, SYSTEMS, THEORETICAL/COMPUTATIONAL NEUROSCIENCE AND BIOMEDICAL ENGINEERING EXPERTISE WILL TAKE A MULTIPRONGED APPROACH TO TEST THE CENTRAL HYPOTHESIS THAT ASTROCYTES SERVE THE FUNCTION OF INTEGRATING NEUROMODULATOR SIGNALS IN CIRCUITS ACROSS THE BRAIN. ASTROCYTES ARE BY SOME ACCOUNTS THE MOST COMMON CELL IN THE BRAIN. THEY HAVE BEEN HISTORICALLY VIEWED AS SUPPORT CELLS FOR NEURAL CIRCUITS, BUT EMERGING EVIDENCE SUGGESTS THAT THEY ARE ACTIVE PARTICIPANTS IN CIRCUIT FUNCTIONS. THIS IS ESPECIALLY INTERESTING BECAUSE ASTROCYTES ARE AFFECTED BY STRESS, AGING, AND MANY DISEASES OF THE CENTRAL NERVOUS SYSTEM. REMARKABLY, ASTROCYTES EXPRESS RECEPTORS FOR SEROTONIN, NOREPINEPHRINE, DOPAMINE, AND ACETYLCHOLINE; THE FOUR NEUROMODULATOR SYSTEMS THAT ARISE FROM DEEP STRUCTURES AND INNERVATE MOST BRAIN CIRCUITS. THESE NEUROMODULATOR SYSTEMS HAVE CONSIDERABLE OVERLAPPING CIRCUIT FUNCTIONS SUGGESTING THAT A MECHANISM FOR INTEGRATING THEIR INPUTS IS IMPORTANT FOR DISAMBIGUATING HOW EACH NEUROMODULATOR EXERTS ITS CONTRIBUTION TO THE CIRCUIT FUNCTIONS. THIS PROJECT WILL TEST THE POSSIBILITY THAT ASTROCYTES PROVIDE SUCH AN INTEGRATOR FUNCTION. THE INVESTIGATORS WILL USE STATE OF THE ARTS TECHNIQUES AND DEVELOP NEW ONES TO TEST HOW ASTROCYTES ARE AFFECTED BY NEUROMODULATORS AND HOW THESE EFFECTS IMPACT CIRCUIT FUNCTIONS AND BEHAVIOR IN TWO BRAIN SYSTEMS. IN VIVO STUDIES WILL TEST THE HYPOTHESIS ON A CELL POPULATION LEVEL MANIPULATING EACH OF THE NEUROMODULATOR CIRCUITS WHILE TESTING ASTROCYTE RESPONSES TO ALL FOUR, CIRCUIT PHYSIOLOGY, AND BEHAVIOR. EX VIVO STUDIES WILL FOCUS ON SINGLE CELL DIFFERENCES IN ASTROCYTES BY COMBINING FUNCTIONAL STUDIES THAT PARALLEL IN VIVO ONES. THESE SPATIALLY RESOLVED FUNCTIONAL STUDIES WILL BE ALIGNED WITH SPATIAL SINGLE CELL TRANSCRIPTOMICS PROVIDING GENE EXPRESSION DATA TO PARALLEL FUNCTIONAL DATA AT SCALE. STRESS AND AGING ARE KNOWN TO IMPACT ASTROCYTES AND NEUROMODULATOR FUNCTIONS AND ADVERSELY AFFECT MANY NEUROPSYCHIATRIC DISEASES. THE TEAM WILL LASTLY ESTABLISH HOW STRESS AND AGING IMPACT THE ABILITY OF ASTROCYTES TO INTEGRATE NEUROMODULATOR SIGNALS USING THEIR CUTTING EDGE TECHNIQUES. COMPLETING THESE AMBITIOUS STUDIES WILL UNEQUIVOCALLY TEST A TRANSFORMATIVE IDEA FOR AN ORGANIZING PRINCIPLE AROUND ASTROCYTE FUNCTION THROUGHOUT THE BRAIN AND INFORM HOW DYSFUNCTION OF THESE CELLS CAN BE CONTRIBUTING TO DISEASES OF THE CENTRAL NERVOUS SYSTEM.

CELLULAR MECHANISMS OF ANTIDEPRESSANT ACTION

PRENATAL FACTORS AND RISK OF SCHIZOPHRENIA IN A FINNISH NATIONAL BIRTH COHORT

OLANZAPINE VERSUS PLACEBO IN OUTPATIENTS WITH ANOREXIA NERVOSA

COGNITIVE AND NEURAL MECHANISMS OF THE ACCELERATED AGING PHENOTYPE IN PTSD

THE NEUROBIOLOGY OF SUICIDAL BEHAVIOR

BREAKING THE CYCLE OF INTERGENERATIONAL DISADVANTAGE: NEURODEVELOPMENT AMONG PUERTO RICAN CHILDREN.

SCALING UP ECONNECT IN JUVENILE PROBATION SETTINGS: A HYBRID IMPLEMENTATION-EFFECTIVENESS TRIAL OF A DIGITAL SUICIDE RISK/BEHAVIOR IDENTIFICATION AND LINKAGE-TO-TREATMENT SYSTEM - AMONG US ADOLESCENTS, SUICIDE IS THE SECOND LEADING CAUSE OF DEATH1. SUICIDE RISK IS NOT UNIFORM ACROSS YOUTH, AND THOSE INVOLVED IN THE JUVENILE JUSTICE (JJ) SYSTEM ARE AT EVEN GREATER RISK FOR SUICIDAL BEHAVIOR (SB) GIVEN THEIR INCREASED PREVALENCE OF MOOD AND SUBSTANCE USE DISORDERS, TRAUMA EXPOSURE, AND ACCESS TO FIREARMS. WHILE SB SCREENING AND SERVICE PROVISION FOR YOUTH IN SECURE JJ SETTINGS OCCURS MORE SYSTEMATICALLY, SUCH PRACTICES ARE RARER FOR YOUTH WHO ARE SUPERVISED IN THEIR COMMUNITY (I.E., PROBATION SETTINGS). THE PROPOSED STUDY WILL EXAMINE STRATEGIES TO BOLSTER THE SUCCESSFUL SCALE-UP OF E-CONNECT, ONE OF THE FEW EVIDENCE-BASED SUICIDE BEHAVIOR IDENTIFICATION AND CROSS-SYSTEM LINKAGE PROGRAMS FOR YOUTH ON UNDER COMMUNITY SUPERVISION. THIS PROPOSAL IS FROM TWO PIS WITH COMPLIMENTARY EXPERTISE IN THE JUSTICE SYSTEM, IMPLEMENTATION SCIENCE, CLINICAL DECISION SUPPORT SYSTEMS, AND USE OF LARGE ADMINISTRATIVE DATA SETS, AND IS SUPPORTED BY A STRONG MULTI- DISCIPLINARY TEAM TO ACHIEVE STUDY AIMS. GUIDED BY THE GATEWAY PROVIDER MODEL (GPM) AND THE EXPLORATION, PREPARATION, IMPLEMENTATION SUSTAINMENT (EPIS) IMPLEMENTATION FRAMEWORK, WE NOW PROPOSE TO EXTEND OURWORK OF E-CONNECT, TO DEVELOP AND TEST A “PURVEYOR MODEL” OF IMPLEMENTATION SCALE-UP (I.E., E-CONNECT-SCALEUP). IN E- CONNECT-SCALEUP, RESEARCHTEAMLEADERSHIPWILL SERVEAS EXTERNAL FACILITATORSTO SUPPORT LOCAL FACILITATORS TO ENSURE THE SUCCESSFUL TRANSFER OF KNOWLEDGE, SKILL AND EXPERTISE IN DELIVERING E-CONNECT IN A NEW JJ SYSTEM AND GEOGRAPHIC CONTEXT, UTILIZING IMPLEMENTATION STRATEGIES TO SUPPORT THE MORE WIDESPREAD, SUSTAINED AND RIGOROUS ADOPTION OF E-CONNECT. WORKING IN 9 INDIANA COUNTIES, RANDOMLY ASSIGNED TO ONE OF THREE WAVES IN A STEPPED- WEDGE, IMPLEMENTATION-EFFECTIVENESSHYBRID TYPE-2 DESIGN ,THE SPECIFICAIMS ARE TO EXAMINE THE CLINICAL AND COST- EFFECTIVENESS OF E-CONNECT-SCALEUP ON (I) IDENTIFICATION OF YOUTH SERVICE NEED (SB AND BH CORRELATES) IN JUVENILE PROBATIONERS; (II) CROSS-SYSTEM (PROBATION-BH AGENCY) REFERRAL; AND (III) YOUTH BH SERVICE USE (INITIAL BH CONTACT; PRIMARY OUTCOME) BY COMPARING THE PERFORMANCE OF E-CONNECT TO (A) STANDARD PROBATION OFFICER PRACTICE (BASELINE) AND (B) TO RATES ACHIEVED IN THE PRIOR EFFICACY TRIAL OF E-CONNECT (AIM 1). WE WILL EXAMINE POTENTIAL MEDIATING OR MODERATING EFFECTS OF EPIS/GPM INNER AND OUTER CONTEXT FACTORS. WE WILL ALSO DETERMINE WHETHER E-CONNECT-SCALEUP CAN REDUCE RACE OR GENDER HEALTH DISPARITIES IN SB/BH SERVICE NEED IDENTIFICATION, CROSS- SYSTEM REFERRAL AND YOUTH SB/BH SERVICE USE (E.G. AS COMPARED TO STANDARD PROBATION PRACTICE (BASELINE), WHICH WOULD REPLICATE THE DISPARITY-REDUCING PERFORMANCE OF E-CONNECT IN NYS (AIM 2). FINALLY, WE WILL EXAMINE THE IMPLEMENTATION OF E-CONNECT-SCALEUP IN TERMS OF FIDELITY AND ACCEPTABILITY AND COMPARE ADVANCEMENT THROUGH THE STAGES OF IMPLEMENTATION THROUGH TO SUSTAINMENT ACROSS THE 9 COUNTIES IN ORDER TO DEMONSTRATE THE FEASIBILITY OF SCALING-UP E-CONNECT IN PROBATION SETTINGS BEYOND NYS (AIM 3). WE WILL ELUCIDATE THE INNER- AND OUTER-LEVEL EPIS- AND GPM- DERIVED FACTORS THAT PROMOTE OR HINDER DELIVERY OF IMPLEMENTATION STRATEGIES AND PRACTICE CHANGE TO INFORM SCALE UP ACROSS A VARIETY OF CONTEXTS.

PATH

IDENTIFYING REPRODUCIBLE BRAIN SIGNATURES OF OBSESSIVE-COMPULSIVE PROFILES

IMPACT OF MEDICAL AND RECREATIONAL MARIJUANA LAWS ON CANNABIS, OPIOIDS AND PSYCHIATRIC MEDICATIONS: NATIONAL STUDY OF VA PATIENTS, 2000 -2024

POSTMORTEM NEUROCHEMICAL STUDIES IN SUICIDE

RECAST BUFFALO - THE NYS OFFICE OF MENTAL HEALTH (OMH) RECAST BUFFALO PROGRAM'S POPULATION OF FOCUS IS BLACK AFRICAN AMERICANS RESIDING IN OR ATTENDING SCHOOL IN FIVE BUFFALO EAST SIDE NEIGHBORHOODS, WITH A SPECIAL FOCUS ON HIGH-RISK YOUTH AND THEIR FAMILIES. THESE NEIGHBORHOODS ARE HIGHLY IMPACTED BY THE RACIALLY MOTIVATED MASS SHOOTING THAT OCCURRED ON MAY 14, 2022. BLACK/AFRICAN AMERICAN YOUTH IN THESE NEIGHBORHOODS EXPERIENCE MULTIPLE RISK FACTORS INCLUDING THE IMPACTS OF STRUCTURAL RACISM, THE COVID PANDEMIC AND SCHOOL DISRUPTION, AND THE TRAUMA OF THE BUFFALO AND UVALDE SHOOTINGS WITH IN 10 DAYS. IN THESE NEIGHBORHOODS, YOUTH AND FAMILIES EXPERIENCE POWERLESSNESS AND SIGNIFICANT BARRIERS TO ACCESSING HIGH-QUALITY EDUCATION AND HOUSING, ADEQUATE HEALTH AND MENTAL HEALTH CARE, AND GOOD JOBS WITH FAIR PAY. CURRENT RESOURCES NEEDS AND GAPS AND CHALLENGES ASSOCIATED WITH ACCESS TO OR QUALITY OF SERVICES IN THESE COMMUNITIES ARE LONG-TERM AND COMPOUNDED BY THE MASS SHOOTING. THE NYS OMH SERG PROGRAM FOR BUFFALO HAS CATALYZED A ONE-YEAR PROCESS OF COMMUNITY PLANNING AND HEALING, WHICH WILL BE SUSTAINED BY RECAST. NYS OMH'S RECAST PROGRAM WILL INCLUDE A COALITION OF DIVERSE COMMUNITY STAKEHOLDERS TO ENSURE THAT COMMUNITY VOICE AND PARTNERSHIP IS INVOLVED IN ALL ASPECTS OF THE GRANT PROJECT, WHICH WILL SUPPORT RECOVERY-ORIENTED, TRAUMA-INFORMED, AND EQUITY-BASED BEHAVIORAL HEALTH AND WELLNESS. THE PROPOSED PROGRAM INCLUDES THREE RECAST FUNDED TRAUMA-INFORMED BEHAVIORAL HEALTH SERVICES:1) A BLACK MENTAL HEALTH RESPONSE TEAM LED BY BESTSELF BEHAVIORAL HEALTH WILL CONTINUE OUTREACH AND ENHANCEMENT WITH YOUTH AND FAMILIES IN THE EAST SIDE; 2) UNIVERSITY PSYCHIATRIC PRACTICE, IN COLLABORATION WITH SAYYES BUFFALO AND THE BUFFALO PUBLIC SCHOOLS, WILL PROVIDE CLINICAL SUPPORTS FOR STUDENTS STRUGGLING WITH COMMUNITY TRAUMA AND TRAINING FOR EDUCATORS; AND 3) BUFFALO COMMUNITY NON-TRADITIONAL MENTAL WELLNESS PROGRAMS WILL CONTINUE A FOCUS ON RESPECTING AND INTEGRATING BLACK/AFRICAN AMERICAN TRADITIONS AND CULTURE TO INCLUDE ARTS-BASED THERAPIES, COORDINATION WITH LOCAL HOUSES OF WORSHIP AND SPIRITUAL-BASED HEALING. IN ADDITION, AFTER PROJECT HOPE CRISIS COUNSELING SERVICES (FEMA-4480-DR-NY) END ON DECEMBER 12, 2022, THE BUFFALO URBAN LEAGUE AND SPECTRUM HEALTH WILL PARTICIPATE IN RECAST TO CONTINUE DELIVERING NYS OMH IN-KIND CRISIS COUNSELING OUTREACH AND ENGAGEMENT SERVICES TO BLACK/AFRICAN AMERICAN FAMILIES AND YOUTH RESIDING IN OR ATTENDING SCHOOLS IN THE EAST SIDE. TRAINING IN TRAUMA-INFORMED CARE AND APPROACHES WILL BE PROVIDED IN -KIND THROUGH THE NYS TRAUMA-INFORMED NETWORK AND VIA INDVIDUALS IN THE COMMUNITY TRAINED BY THE NYS OMH SERG PSYCHOLOGICAL FIRST AID TRAIN-THE-TRAINER. RECAST FUNDING IS REQUESTED FOR YOUTH AND FAMILY PEER SERVICES THAT WILL BE INTEGRATED INTO THIS WORK. GIVEN THE SHORTAGE OF BLACK/AFRICAN AMERICAN YOUTH AND FAMILY PEER ADVOCATES IN BUFFALO, NYS OMH WILL PARTNER WITH PEER-RUN ORGANIZATIONS TO BUILD WORKFORCE PIPELINES FOR BLACK/AFRICAN AMERICAN FAMILIES AND YOUTH TO BECOME CREDENTIALED. THE PROPOSED RECAST PROJECT GOALS ARE: GOAL 1: BUILD A COMMUNITY COALITION REPRESENTING BUFFALO'S BLACK/AFRICAN AMERICAN COMMUNITY THAT IS EMPOWERED TO ASSESS AND PLAN FOR HIGH-RISK YOUTH AND FAMILIES IMPACTED BY THE MASS SHOOTING. GOAL 2: INCREASE LOCAL MH CAPACITY FOR TRAUMA-INFORMED AND CULTURALLY COMPETENT BEHAVIORAL HEALTH SERVICES, INCLUDING YOUTH AND FAMILY PEER SERVICES, IN BUFFALO'S EAST SIDE THROUGH TRADITIONAL WELLNESS APPROACHES IN SCHOOLS AND THE COMMUNITY. GOAL 3: INCREASE ACCESS TO TRAUMA-INFORMED TRAINING TO EMPOWER LOCAL COMMUNITY TO RESPOND TO NEEDS OF BLACK/AFRICAN AMERICAN YOUTH FAMILIES, AND COMMUNITY MEMBERS IN A TRAUMA-INFORMED AND CULTURALLY COMPETENT MANNER. EACH RECAST GOAL HAS A SET OF MEASURABLE OBJECTIVES IDENTIFIED BY TIMEFRAMES. WE ESTIMATE THAT APPROXIMATELY 3,806 UNDUPLICATED INDIVIDUALS WILL BE SERVED DURING THE FOUR YEARS OF THE PROJECT. Y1-370; Y2-967; Y3-1,242; Y4-1,227; TOTAL 3,806

PIPBHC - THE NEW YORK STATE OFFICE OF MENTAL HEALTH (NYSOMH) WILL IMPLEMENT ACCESS-NY (ADVANCING COLLABORATIVE CARE FOR EVIDENCE-BASED, SUSTAINABLE SYSTEMS), A STATEWIDE INITIATIVE TO EXPAND THE COLLABORATIVE CARE MODEL (COCM) IN HIGH-NEED COMMUNITIES. ACCESS-NY WILL ESTABLISH COCM IN EIGHT NEW FEDERALLY QUALIFIED HEALTH CENTER AND RURAL HEALTH CLINIC PRACTICES AND TREAT AN ESTIMATED 1,750 INDIVIDUALS AGES 6 AND OLDER WITH CHRONIC PHYSICAL HEALTH CONDITIONS AND CO-OCCURRING MENTAL HEALTH DISORDERS AND SUBSTANCE USE DISORDERS OVER FIVE YEARS. COMMUNITY MENTAL HEALTH CENTERS WILL SUPPORT BIDIRECTIONAL INTEGRATION NETWORKS. THE PROJECT WILL USE TECHNOLOGY TO IMPROVE TRACKING AND DOCUMENTATION, PROVIDE TECHNICAL ASSISTANCE AND CLINICAL SUPPORT FOR KEY PRACTICE ROLES, AND HELP SITES TAILOR BIDIRECTIONAL CARE TO PATIENT NEEDS. ACCESS-NY WILL ALSO DEVELOP WEB-BASED TRAINING CURRICULA TO BROADEN INTEGRATED CARE SKILLS AND EXAMINE USE OF CREDENTIALED MENTAL HEALTH SUPPORT SPECIALISTS AND REGISTERED NURSES AS BEHAVIORAL HEALTH CARE MANAGERS IN COCM. THE PROJECT AIMS TO IMPROVE ACCESS TO INTEGRATED BEHAVIORAL AND PHYSICAL HEALTH CARE, STRENGTHEN WORKFORCE CAPACITY, AND SUPPORT SUSTAINED ADOPTION OF EVIDENCE-BASED INTEGRATED CARE MODELS.

REGION 2 ATTC: NJ, NY, PR & THE U.S. VI

IMPROVING LIFE TRAJECTORIES FOR YOUTH WITH EARLY PSYCHOSIS

THE IMPACT OF 9/11 ON YOUTH: MENTAL HEALTH, SUBSTANCE USE & OTHER RISK BEHAVIORS

PHENOTYPES FOR DRUG ABUSE:EPIDEMIOLOGIC-GENETIC APPROACH

LONGITUDINAL ASSESSMENT OF NEURAL CIRCUITS IN ADOLESCENTS WITH ANOREXIA NERVOSA

SINGLE-CELL AND TARGET-SPECIFIC RESOLUTION OF MULTIPLE MEMORIES ACROSS THE BRAIN

CRISIS COUNSELING

PATERNAL CRIMINAL JUSTICE INVOLVEMENT AND SUBSTANCE USE IN CHILDREN & ADOLESCENTS

TEMPORAL DYNAMICS OF NEUROPHYSIOLOGICAL PATTERNS AS TREATMENT TARGETS IN SZ

SOCIAL CONVOYS, COGNITIVE RESERVE AND RESILIENCE, AND RISK FOR ALZHEIMER'S DISEASE AND RELATED DEMENTIAS

MRI: DEVELOPMENT OF A NEXT GEN 9.4T MAGNETIC RESONANCE SYSTEM FOR TRANSLATIONAL NEUROSCIENCE

CELLULAR MECHANISMS OF ANTIDEPRESSANT ACTION

SOCIAL PROCESSING DEFICITS IN REMITTED ADOLESCENT DEPRESSION

THE NKI ROCKLAND SAMPLE II: AN OPEN RESOURCE OF MULTIMODAL BRAIN, PHYSIOLOGY & BEHAVIOR DATA FROM A COMMUNITY LIFESPAN SAMPLE - ABSTRACT. THE PRESENT COMPETING RENEWAL APPLICATION PROPOSES TO CREATE THE NEXT GENERATION NKI-ROCKLAND SAMPLE (NKI-RS) INITIATIVE. THE NKI-ROCKLAND SAMPLE (NKI-RS) HAS SERVED AS A BEACON FOR LIFESPAN CONNECTOMICS RESEARCH, PROVIDING A MODEL FOR ACCELERATING THE PACE OF PSYCHIATRIC DISCOVERY SCIENCE. MORE THAN 200 PUBLICATIONS HAVE USED NKI-RS, GENERATED LARGELY BY INDEPENDENT INVESTIGATORS AND IN MAJOR JOURNALS. SINCE 2011, IT HAS GENERATED AND PUBLICLY SHARED (ON A QUARTERLY BASIS) A LARGE-SCALE (N > 1400), DEEPLY PHENOTYPED, COMMUNITY-ASCERTAINED, CROSS-SECTIONAL, LIFESPAN SAMPLE (AGES 6–85 YEARS OLD) WITH ADVANCED CONNECTOMICS- FOCUSED NEUROIMAGING (I.E., DIFFUSION MRI, RESTING STATE FMRI [R-FMRI]) AND GENETIC SAMPLES. RECENTLY LAUNCHED LARGE- SCALE EFFORTS, SUCH AS THE HCP LIFESPAN STUDIES AND THE NIH ABCD STUDY ARE WORKING TO BRING TO SCALE HUMAN CONNECTOME MAPPING AND BRAIN FUNCTION ACROSS THE LIFESPAN, USING ‘BATTLE-TESTED’ IMAGING TECHNOLOGIES AND STRATEGIES. THESE ONGOING STUDIES ARE LESS FOCUSED ON MENTAL HEALTH. MOREOVER, TECHNOLOGIES AND IDEAS CONTINUE TO EVOLVE - OFTEN TOO RAPIDLY TO PERMIT TIMELY TESTING AND INCLUSION IN ONGOING RESEARCH. THE OVERARCHING GOAL OF THE PRESENT PROPOSAL IS TO CREATE THE NEXT GENERATION NKI-RS INITIATIVE THAT WILL ONCE AGAIN EXTEND THE VANGUARD IN THE STUDY OF LIFESPAN CONNECTOMICS BY ENRICHING AND EXPANDING THE LANDSCAPE FOR NEUROSCIENTIFIC ADVANCEMENT AND BIOMARKER DISCOVERY. THREE MAJOR THEMES HAVE GUIDED THE DESIGN OF THE PROPOSED NKI-RS-II LIFESPAN RESOURCE: 1) MULTIMODAL MEASUREMENT INTEGRATION ACROSS FUNCTIONAL DOMAINS (E.G., FMRI, EEG, MOBILE BRAIN/BODY IMAGING [MOBI] FRAMEWORK), 2) ECOLOGICAL SAMPLING (E.G., WEARABLES, SENSORS, SMARTPHONES APPS), AND 3) ENHANCED PHYSIOLOGICAL PHENOTYPING FOR CARDIOVASCULAR FITNESS AND OBESITY. SPECIFICALLY, IN A COMMUNITY- ASCERTAINED LIFESPAN SAMPLE (N=600; AGES 9-75; M: F = 1:1; AGE RANGE SELECTED TO MAXIMIZE DATA YIELD AND TOLERABILITY), THE PROPOSED WORK AIMS TO: 1) GENERATE AND SHARE LARGE-SCALE MULTIMODAL MRI/EEG IMAGING DATA COMPLEMENTED BY COMPREHENSIVE PHENOTYPING OF COGNITION, BEHAVIOR, AND PSYCHIATRIC STATUS, FROM HUMAN AND SENSOR-BASED INFORMANTS; 2) OPTIMIZE BRAIN-AGE PREDICTION ACROSS THE LIFESPAN USING MULTIMODAL DATA (R-FMRI, NATURALISTIC VIEWING FMRI [NV-FMRI], DMRI, T2/T1, R-EEG, NV-EEG) AND RELATE DEVIATIONS FROM CHRONOLOGICAL AGE TO DIMENSIONS OF PSYCHOPATHOLOGY AND COGNITIVE PERFORMANCE; AND 3) IDENTIFY THE RELATIONSHIP OF MODIFIABLE HEALTH RISK FACTORS (E.G., FITNESS, OBESITY, PHYSICAL ACTIVITY, SUBSTANCE USE) TO DEVIATIONS BETWEEN PREDICTED BRAIN AGE AND CHRONOLOGICAL AGE ACROSS THE LIFESPAN. CONSISTENT WITH THE MODEL ESTABLISHED BY THE PREVIOUSLY FUNDED NKI-RS INITIATIVES, ALL DATA WILL BE SHARED PROSPECTIVELY, ON A QUARTERLY BASIS, VIA THE INTERNATIONAL NEUROIMAGING DATA-SHARING INITIATIVE (INDI) AND THE NIMH DATA ARCHIVE (NDA).

MATERNAL INCARCERATION AND COURSE OF CHILD PSYCHOPATHOLOGY IN THE SOUTH BRONX

LONGITUDINAL DISCOVERY OF BRAIN DEVELOPMENTAL TRAJECTORIES

NYS OASAS PREVENTION OF OVERDOSE THROUGH OUTREACH TO FAMILIES - THE NEW YORK STATE OFFICE OF ADDICTION SERVICES AND SUPPORTS (NYS OASAS) PREVENT PRESCRIPTION DRUG/OPIOID OVERDOSE-RELATED DEATHS PROJECT, TITLED PREVENTION OF OVERDOSE THROUGH OUTREACH TO FAMILIES (POOF) WILL EXPAND AND ENHANCE OVERDOSE PREVENTION SERVICES IN NEW YORK. TO THAT END, OASAS WILL COLLABORATE WITH THE PARTNERSHIP TO END ADDICTION TO CREATE A COMPREHENSIVE OVERDOSE PREVENTION TRAINING. OVER THE COURSE OF FIVE YEARS, OASAS WILL PARTNER WITH THE NEW YORK STATE DEPARTMENT OF HEALTH (DOH) AND THE NEW YORK STATE OFFICE OF CHILDREN AND FAMILY SERVICES (OCFS) IN ORDER TO PROVIDE THIS TRAINING AND NALOXONE TO THEIR FRONTLINE STAFF IN PROGRAMS SUCH AS OCFS MANAGED DOMESTIC VIOLENCE SHELTERS, HEALTHY FAMILIES NEW YORK HOME VISITING PROGRAM, AND THE MATERNAL AND INFANT COMMUNITY HEALTH COLLABORATIVES. FURTHERMORE, THE SAMHSA TOOLKIT FOR OPIOID OVERDOSE PREVENTION WILL BE UTILIZED TO GUIDE THIS PROCESS. THROUGH THIS WORK, WE HOPE TO REACH UNDERSERVED POPULATIONS BY FOCUSING ON NONTRADITIONAL TREATMENT SETTINGS, INCLUDING BUT NOT LIMITED TO PREGNANT AND PARENTING WOMEN, LGBTQ+ IDENTIFIED PERSONS, TRIBAL COMMUNITIES, AND PERSONS EXPERIENCING INTIMATE PARTNER VIOLENCE. IT IS EXPECTED IN THE FIRST YEAR OF THE GRANT TO TRAIN A TOTAL OF 750 INDIVIDUALS IN OVERDOSE PREVENTION. IN YEAR TWO, THIS NUMBER WILL INCREASE TO 3,000, AND THEREAFTER 4,000 PEOPLE WILL BE TRAINED PER YEAR FOR A TOTAL OF 15,750 UNDUPLICATED PERSONS TRAINED BY THE END OF YEAR 5. OASAS WILL DEVELOP SYSTEMS AND PROCEDURES DEEMED NECESSARY TO SUSTAIN THESES PROPOSED SERVICES BEYOND THE FIVE-YEAR GRANT PERIOD TO CONTINUE EXPANDING PREVENTION SERVICES. SPECIFIC GOALS OF THE PREVENTION OF OVERDOSE THROUGH OUTREACH TO FAMILIES INCLUDE: (1) IDENTIFY AREAS OF GREATEST NEED IN RELATION TO PRESCRIPTION DRUG/OPIOID OVERDOSE IN NEW YORK, (2) INCREASE ACCESS TO OPIOID AND PRESCRIPTION DRUG OVERDOSE AND KNOWLEDGE OF OVERDOSE TRAINING IN NEW YORK, (3) INCREASE THE NUMBER OF OPIOID OVERDOSE PREVENTION MASTER TRAINERS IN NONTRADITIONAL SETTINGS, (4) INCREASE ACCESS TO OVERDOSE PREVENTION TRAININGS AND RESOURCES IN NONTRADITIONAL, NON-OASAS SETTINGS, AND (5) INCREASE ACCESS TO AND AWARENESS OF TREATMENT SERVICES.

LONG-LASTING CONSEQUENCES OF EARLY ETHANOL ON NETWORK ACTIVITY DURING SLEEP

INVESTIGATING THE ROLE OF HIPPOCAMPUS - ORBITOFRONTAL CIRCUITS FOR COGNITIVE FLEXIBILITY - PROJECT SUMMARY COGNITIVE FLEXIBILITY ALLOWS AN INDIVIDUAL TO ADAPT ESTABLISHED THINKING PATTERNS AND BEHAVIORAL RESPONSES TO NOVEL SITUATIONS THAT MAY REQUIRE NEW APPROACHES THAN THOSE THAT WERE PREVIOUSLY LEARNED IN ORDER TO BE SOLVED CORRECTLY. COGNITIVE FLEXIBILITY IS THEREFORE NECESSARY TO FLEXIBLY ADJUST ONES THINKING AND BEHAVIOR INSTEAD OF RUMINATING OVER THOUGHTS AND WORRIES, OR INSTEAD OF SHOWING HABITUAL BEHAVIOR THAT MAY NOT BE PRODUCTIVE TO EFFECTIVELY ENGAGE WITH A NEW SITUATION OR TO SOLVE A NEW PROBLEM. IMPAIRMENTS IN COGNITIVE FLEXIBILITY CAN OCCUR AS A RESULT OF CHRONIC STRESS, WHICH IS A MAJOR CONTRIBUTOR TO THE PATHOGENESIS OF MANY PSYCHIATRIC DISORDERS. ACCORDINGLY, COGNITIVE FLEXIBILITY DEFICITS ARE COMMON ACROSS A WIDE RANGE OF MENTAL ILLNESSES AND OFTEN UNRESPONSIVE TO OTHERWISE EFFECTIVE MEDICATION. MOREOVER, INDIVIDUALS WITH HIGH LEVELS OF COGNITIVE FLEXIBILITY HAVE BEEN SHOWN TO COPE BETTER WITH DAY-TO-DAY STRESSORS, AND TO BE LESS VULNERABLE TO DEVELOPING PSYCHIATRIC DISORDERS. IF WE CAN UNDERSTAND THE NEURAL CIRCUITS UNDERLYING COGNITIVE FLEXIBILITY, WE MAY BE ABLE TO IDENTIFY NEW TARGETS FOR ADVANCED THERAPEUTICS TO TREAT THE DEBILITATING COGNITIVE IMPAIRMENTS OF MANY PSYCHIATRIC DISORDERS. IN THIS PROPOSAL, WE WILL STUDY A NOVEL NEURAL CIRCUIT COMPONENT UNDERLYING ONE IMPORTANT FORM OF COGNITIVE FLEXIBILITY: REVERSAL LEARNING. WE WILL SPECIFICALLY INVESTIGATE HOW NEURAL PROJECTIONS FROM THE VENTRAL HIPPOCAMPUS TO THE ORBITOFRONTAL CORTEX (OFC) REGULATE REVERSAL LEARNING AND STRESS RESILIENCE. IN AIM 1, WE WILL INHIBIT DIRECT INPUT PROJECTIONS FROM THE VENTRAL HIPPOCAMPUS TO THE MEDIAL OFC, AND OUTPUT PROJECTIONS FROM THE MEDIAL OFC TO THE LATERAL OFC, TO TEST IF THIS CIRCUIT IS FUNCTIONALLY IMPORTANT FOR REVERSAL LEARNING. IN AIM 2, WE WILL USE IN VIVO CA2+ IMAGING OF NEURAL ACTIVITY IN VENTRAL HIPPOCAMPUS, MEDIAL OFC, AND LATERAL OFC, TO EXAMINE FOR THE FIRST TIME HOW NEURONS IN THESE BRAIN REGIONS STORE, PROCESS, AND UPDATE INFORMATION ABOUT ACTION-OUTCOME VALUE ASSOCIATIONS THAT ARE IMPORTANT FOR REVERSAL LEARNING. IN AIM 3, WE WILL THEN INVESTIGATE HOW THESE SAME BRAIN REGIONS BECOME DYSFUNCTIONAL UNDER CONDITIONS OF CHRONIC STRESS, AND IF STIMULATING THIS CIRCUITRY CAN CONFER STRESS RESILIENCE AND COUNTERACT STRESS-INDUCED DEFICITS IN REVERSAL LEARNING. TOGETHER, THESE EXPERIMENTS WILL PROVIDE FIRST INSIGHT INTO A NEW ELEMENT OF THE NEURAL CIRCUITRY UNDERLYING COGNITIVE FLEXIBILITY AND STRESS RESILIENCE, WHICH HAS GREAT POTENTIAL TO REVEAL NEW NEURAL CIRCUIT-BASED TARGETS FOR NOVEL DRUGS OR FOR ADVANCED COGNITIVE-BEHAVIORAL THERAPIES AIMED AT IMPROVING COGNITIVE FLEXIBILITY IN PATIENTS SUFFERING FROM PSYCHIATRIC DISORDERS.

DEFICIENT BELIEF UPDATING AS A CONVERGENT COMPUTATIONAL MECHANISM OF PSYCHOSIS

AN INTEGRATIVE COMPUTATIONAL INTERROGATION OF CIRCUIT DYSFUNCTION INSCHIZOPHRENIA VIA NEURAL TIMESCALES - SUMMARY/ABSTRACT SCHIZOPHRENIA IS A DEVASTATING AND BURDENSOME ILLNESS THE MECHANISMS OF WHICH REMAIN ELUSIVE. CONTRIBUTING TO THEIR ELUSIVENESS ARE A HIGHLY COMPLEX SET OF GENETIC FACTORS, PROPOSED ETIOLOGICAL AND PATHOPHYSIOLOGICAL PATHWAYS, AND PHENOTYPIC MANIFESTATIONS. TO ADDRESS THIS COMPLEXITY, WE PROPOSE A HYBRID METHOD COMBINING DATA-DRIVEN APPROACHES TO LARGE-SCALE MULTIMODAL DATASETS AND THEORY-DRIVEN COMPUTATIONAL APPROACHES IN ORDER TO PROVIDE A THEORETICALLY CONSTRAINED FRAMEWORK BRIDGING GENETICS, DEVELOPMENT, CIRCUIT FUNCTION, COGNITION, AND PHENOMENOLOGY OF SCHIZOPHRENIA. TO THAT END, AND IN RESPONSE TO ‘NOTICE OF SPECIAL INTEREST REGARDING THE USE OF HUMAN CONNECTOME DATA (HCP) FOR SECONDARY ANALYSIS’, WE WILL USE DATA FROM UP TO 64,000 INDIVIDUALS, INCLUDING HEALTHY INDIVIDUALS AND PATIENTS WITH SCHIZOPHRENIA AND OTHER DISORDERS, FROM VARIOUS HCP-RELATED PROJECTS AS WELL AS THE UK BIOBANK. WE SPECIFICALLY PROPOSE MEASURING INTRINSIC NEURAL TIMESCALES (INT) FROM RESTING-STATE FMRI DATA AS A THEORY-DRIVEN INDEX OF EXCITATION/INHIBITION (E/I) IMBALANCE IN CORTICAL MICROCIRCUITS. FIRST, EXTENDING OUR PRIOR WORK WE AIM TO CONFIRM AND FURTHER CHARACTERIZE INT ALTERATIONS IN SCHIZOPHRENIA (WIDESPREAD TRAIT-LIKE INT REDUCTIONS AND LOCAL HIERARCHY-DEPENDENT INT MODULATIONS IN RELATION TO PSYCHOTIC SYMPTOMS) AND TO TEST THEIR SPECIFICITY RELATIVE TO OTHER DISORDERS. SECOND, WE WILL EVALUATE THE DEVELOPMENTAL TRAJECTORIES OF INT AND CHARACTERIZE THE GENETIC PROFILE OF THIS FMRI MEASURE AND ITS OVERLAP WITH THE GENETIC PROFILE FOR SCHIZOPHRENIA RISK. THIRD, GIVEN THE ROLE OF E/I RATIO IN CORTICAL MICROCIRCUITS IN SUPPORTING WORKING-MEMORY COMPUTATIONS, WE WILL EXAMINE THE RELATIONSHIP BETWEEN INT AND WORKING-MEMORY ACTIVATION AND PERFORMANCE. WE WILL FURTHER SEEK TO ESTABLISH INT AS A CIRCUIT-LEVEL MEDIATOR OF POLYGENIC RISK FOR SCHIZOPHRENIA ON COGNITIVE DEFICITS. THROUGHOUT, WE WILL USE WELL-POWERED, RIGOROUS, STATE-OF-THE-ART FMRI AND STATISTICAL DATA-DRIVEN METHODS SUITABLE FOR LARGE-SCALE STUDIES AND HCP-STYLE FMRI SEQUENCES, INCLUDING CROSS- VALIDATION AND TESTS OF GENERALIZABILITY. TOGETHER WITH A STRONG THEORETICAL FOUNDATION AND USING BIOPHYSICAL MODELING TO COMPLEMENT FMRI ANALYSES, THIS HYBRID—THEORY- AND DATA-DRIVEN—APPROACH WILL FACILITATE AN INTEGRATED UNDERSTANDING OF THE CIRCUIT-LEVEL MECHANISMS BRIDGING DISTAL GENETIC-RISK FACTORS AND PROXIMAL MANIFESTATIONS OF SCHIZOPHRENIA. IN PARTICULAR, THE COMBINATION OF CUTTING-EDGE CELL-TYPE ENRICHMENT ANALYSES OF GWAS (WHICH IN SCHIZOPHRENIA HAVE SUGGESTED CONVERGING ENRICHMENT IN EXCITATORY AND INHIBITORY CORTICAL CELLS) AND BIOPHYSICAL MODELING AT THE LEVEL OF CORTICAL MICROCIRCUITS OF INTERACTING EXCITATORY AND INHIBITORY CELLULAR POPULATIONS WILL PROVIDE AN INTERPRETATION OF DISPARATE DATA IN TERMS OF CONVERGENT CELL- AND CIRCUIT-LEVEL PATHWAYS. IN DOING SO, THIS PROJECT WILL VALIDATE A THEORETICALLY INFORMATIVE, INTERPRETABLE, TRANSLATABLE, AND SCALABLE RESTING-STATE FMRI MEASURE—INT—THAT MAY BE RELEVANT ACROSS SEVERAL DISORDERS AND, WHICH ADDITIONALLY OWING TO ITS HIGH RELIABILITY AND EASE OF ACQUISITION, HAS HIGH POTENTIAL AS A CANDIDATE BIOMARKER.

NEW YORKERS ADVANCING SUICIDE SAFER CARE FOR YOUTH (NYASSC FOR YOUTH)

SUICIDAL BEHAVIOR IN MOOD DISORDERS:GENES AND INTERMEDIATE PHENOTYPES

UNIVERSAL FOR ALL, FREQUENT FOR SOME: HIV TESTING IN SCHOOL-BASED HEALTH CENTERS

CORTICAL-SUBCORTICAL INTERACTION IN PD AND NORMAL SPEECH

HEALTHCALL: ENHANCING BRIEF INTERVENTION FOR HIV PRIMARY CARE ALCOHOL DEPENDENCE